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eAppendix. Additional Information Concerning the Methods Used, Results and PRIMROSE Model Formulas

Methods
Follow-up period and baseline
The start of follow-up (baseline) for each patient was the latest of: 1 st January 1995, the practice meeting acceptable THIN data quality standards, the patient being registered at a THIN practice for a year, or the patient's 30 th birthday. Their end date was the earliest entry of a new CVD event, the patient or the practice exiting the THIN database, death or 31 st December 2010. We excluded individual patients with less than a year's follow-up data after registration to allow time for patient history and risk factor information to be captured. We further excluded those who had a diagnosis of CVD prior to baseline, those who were already prescribed statins at baseline (since risk scores are used to guide statin treatment), or those who had a record of dementia within one year of their SMI diagnosis (as the diagnosis of SMI was likely to be misclassification of dementia). We excluded the small number of people with missing Townsend deprivation data, which is based on their post code (a geographical marker similar to a US zip code and covering around 150 households).
Variable definition
The variables we considered for inclusion in the PRIMROSE risk model included all variables in the current general CVD Framingham scores 1 namely age in years and the baseline data on: predominant smoking status (current, non-smoker or ex-smoker), lipids (total cholesterol and HDL cholesterol) or BMI (incorporated as height and weight separately), systolic blood pressure and prescription of anti-hypertensive to indicate treatment of hypertension, and history of diabetes mellitus. Given that the Framingham risk score has separate models for men and women we undertook exploratory analyses, modeling the associations of the different predictors with CVD separately for men and women. These analyses revealed comparable relationships between each variable and CVD risk by gender, thereby justifying combination of men and women into a single model. We then considered additional variables which may be relevant for predicting CVD risk in people with SMI, namely social deprivation (as quintiles of the Townsend Index, a widely used measure of deprivation 2 which comprises four domains including levels of car/home ownership, unemployment and overcrowding. It has been used in other risk score development studies in the UK general population and primary care database studies 3 ), history of very heavy alcohol use (defined as more than 56 units per week for men or 49 units per week for women or an entry in their medical records indicating an alcohol problem), SMI diagnostic sub-type (schizophrenia-like disorders, bipolar disorders, other psychoses, specific SMI diagnosis unknown but on general practice SMI register) and baseline use of antipsychotics (first generation and/or second generation), antidepressants (as a marker for significant depression), and lithium. Patients were identified as exposed to these medications if they had received at least two consecutive prescriptions within 6 months (suggesting the first had been taken, requiring a re-issue). Calendar year was also included to account for known time trends in CVD incidence.
Analysis 1) Model development
We developed two risk scores. The first model (PRIMROSE lipid model) included total cholesterol and HDL cholesterol, but not BMI or height and weight. The second model (PRIMROSE BMI model) included height and weight, but not lipid levels. This was in line with the currently published Framingham CVD risk algorithms 1 . The BMI model enables computation of a patient's risk in the absence of laboratory test results. Individuals were assumed to have SMI throughout their follow-up period, since they were all aged over 30 years old and most incident cases of SMI occur prior to this age. We derived the PRIMROSE risk models using Cox proportional hazards regression modelling. Robust standard errors were used to account for clustering of patients within general practices. The assumption of proportional hazards was checked using Schoenfeld residuals 4 and plots of the log cumulative hazard function. Continuous variables (age, SBP, total cholesterol, HDL cholesterol, height, weight, calendar year) were centered around their mean value and the assumption of a linear relationship was assessed using fractional polynomials and transformations made when linear relationships were not confirmed. We initially forced the Framingham risk score variables 1 and gender into the models. We then used backwards elimination to determine which of the additional SMI-specific variables above (e.g. SMI diagnosis) should be retained, using the Akaike's Information Criteria 5 .We subsequently included one interaction term, between SBP and treatment with anti-hypertensive medication, in line with other published CVD risk scores.
2) Missing data
All variables considered for the risk scores were complete except for: smoking, height, weight, Systolic Blood Pressure and total and HDL cholesterol which had some missing data. However, although a patient may be missing a measurement of these incomplete variables at baseline, many such patients have measurements of these variables at subsequent time points during their follow-up. We used the twofold Fully Conditional Specification (FCS) method for multiple imputation of longitudinal datasets, to impute the missing data 6, 7 . The twofold FCS multiple imputation method is an efficient way to make use of the full longitudinal record rather than just the baseline measurements. The imputation model included baseline measurements of all variables listed in the model development section above, plus the outcome and Nelson Aalen cumulative hazard function, plus available measurements at other time points for those variables which vary over time (e.g. blood pressure). We created ten imputed datasets. Greater numbers of imputations were not manageable computationally due to the size of our dataset. The backwards elimination process for the model development described above was carried out separately in each imputed dataset. The variables under consideration were included in the final PRIMROSE models if they were retained after the backwards elimination in 7 out of 10 imputed datasets 8,9. 
3) Sample size calculation
We conservatively estimated that 20 events would be required per coefficient to fit the risk models 10 . The variables we assessed resulted in a total of 25 coefficients at most (before eliminations), including the interaction between anti-hypertensive use and Systolic Blood Pressure, corresponding to 500 CVD events. To account for the clustered nature of the data, with patients nested within practices 11 an inflation factor of 3.88 was applied, based on an intra-class correlation coefficient of 0.022 estimated from the data and a mean cluster size of 90 people with SMI per practice, and a standard deviation of cluster size of 61. This resulted in a required 1939 CVD events in total.
4) Model Validation
We carried out a 10-fold internal cross validation. Essentially this involves splitting the cohort into ten random "test sets", based on the general practices patients were registered with, each containing an equal number of practices. While all practices are included in the development of the final PRIMROSE models, for the cross validation, a test set is omitted from the cohort and the model is re-built within the remaining nine test sets and then tested on the omitted test set. This is repeated excluding a different tenth of the general practices each time. We assessed the discriminative performance of the PRIMROSE models by estimating the C 12 and the D statistics 13 separately for each test set (with analytical 95% confidence intervals for the D statistic and bootstrap confidence intervals for the C statistic). We used Uno's version of the C statistic as it has been shown to be less biased to censoring than other C statistics. We also calculated an overall point estimate for these statistics by combining predicted values from all the test sets from each separate validation. We created calibration plots for the models, using the combined predictions from the validation test sets, comparing the observed and predicted CVD risk per decile of predicted risk. . We compared the performance of the PRIMROSE models with the most contemporary published Framingham models, the Cox Framingham 1 to see if PRIMROSE offered an improvement in prediction. We applied the published cox Framingham risk scores to our SMI cohort (both the Framingham lipid score and the Framingham BMI score) and calculated the same model performance statistics to assess their performance in individuals with SMI.
Finally we compared the percentage of high risk SMI patients identified by the PRIMROSE models and the published Framingham models who actually went on to develop a CVD event over ten years. We chose a cut-off score of 20% to define high risk, as this is the conventional level currently used in practice with existing risk scores.
The validations were carried out separately for men and women, since the Framingham models are published separately for men and women 1 .
5) Supplementary and confirmatory analyses
We assessed the performance of additional models against our new PRIMROSE models, to determine whether using a new CVD risk model for people with SMI was justifiable. Because the coefficients in the Cox Framingham equation 1 are estimated from a North American population, we aimed to assess firstly whether any differences in the performance of the PRIMROSE model and the published Cox Framingham model could simply be due to the SMI cohort being derived from the UK population, and differences in CVD risk between these two countries as opposed to specific characteristics of the SMI cohort. Therefore we re-estimated the coefficients for each of the variables in the published Cox Framingham equation, but using a random selected cohort of 55,525 UK general practice patients. They were from the same 430 general practices in THIN as our SMI cohort and met the same inclusion criteria, namely being aged 30-90 years and free of CVD and statins at baseline. We called this model "the Cox Framingham model, re-estimated for the UK general population". We then evaluated this model within the PRIMROSE SMI cohort to compare its performance against the more complex, new PRIMROSE model. This would determine whether CVD risk models derived from the UK general population are accurate enough to employ in people with SMI. Secondly, we explored whether any further differences in performance between the "Cox Framingham models, re-estimated for the UK general population" and the PRIMROSE models were due to the inclusion of the additional SMI-specific variables in the PRIMROSE models or simply because the PRIMROSE models were constructed using an SMI population.. Therefore we also re-estimated the coefficients for the variables in the published Cox Framingham equations, based on our SMI cohort. We called these models "the cox Framingham models, re-estimated to the SMI cohort". We evaluated these additional models within our SMI cohort to compare their performance against the more complex, new PRIMROSE models.
All analyses were performed using Stata version 12.1.
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